You are here: Home » Current Affairs » Coronavirus » News
Business Standard

15 million doses of J&J coronavirus vaccine ruined in US by 'human error'

The problem at the plant has been reported to be an ingredient mix-up due to "human error"

Johnson & Johnson | United States | Vaccine

IANS  |  New York 

Johnson & Johnson
Photo: Reuters

Errors at a manufacturing plant in the US has ruined 15 million potential doses of the Covid-19 vaccine, The New York Times reported.

The quality issue was identified at a manufacturing plant in Baltimore run by Emergent Biosolutions, a site not yet authorised to manufacture drug substance for Johnson & Johnson's Covid-19

The error is delaying the authorisation of the plant's production lines as the US Food and Drug Administration (FDA) investigates what occurred.

Emergent Biosolutions is also a manufacturing partner for AstraZeneca, whose Covid-19 has not yet been approved in the US.

The problem at the plant has been reported to be an ingredient mix-up due to "human error".

No issues were reported for the doses that are being delivered and used in the US currently though.

Those doses were manufactured in the Netherlands, where production lines have been fully approved by federal regulators, the Times reported on Wednesday.

said in a statement that the "quality control process identified one batch of drug substance that did not meet quality standards at Emergent Biosolutions, a site not yet authorized to manufacture drug substance for our Covid-19 vaccine."

"This batch was never advanced to the filling and finishing stages of our manufacturing process," the company said.

According to a report in The Verge, about 30 per cent of the US population has received at least one dose of a Covid-19 vaccine so far.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 01 2021. 15:12 IST